▶ 調査レポート

免疫タンパク質診断検査の世界市場:成長・動向・市場規模予測(2020-2025)

• 英文タイトル:Immunoprotein Diagnostic Testing Market- Growth, Trends, and Forecast (2020 - 2025)

Mordor Intelligenceが調査・発行した産業分析レポートです。免疫タンパク質診断検査の世界市場:成長・動向・市場規模予測(2020-2025) / Immunoprotein Diagnostic Testing Market- Growth, Trends, and Forecast (2020 - 2025) / D0-MOR-AP0685資料のイメージです。• レポートコード:D0-MOR-AP0685
• 出版社/出版日:Mordor Intelligence / 2020年4月20日
• レポート形態:英文、PDF、117ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:健康管理
• 販売価格(消費税別)
  Single User¥463,250 (USD4,250)▷ お問い合わせ
  Team User¥517,750 (USD4,750)▷ お問い合わせ
  Corporate License¥817,500 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは、免疫タンパク質診断検査の世界市場について調査・分析した資料で、免疫タンパク質診断検査の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。

The immunoprotein diagnostic testing market is expected to grow due to growing burden of chronic diseases and technological advancements related to the products. According to the Institute of Health Metrics and Evaluation, DALYS (Disability-adjusted Life Years) is a tool to measure the burden of diseases. It determines the years lost due to diseases. The countries below 20,000 per 100,000 DALYS are cosidered to be healthy. In 2017, Sub-Saharan African Region were reported with around 80,000 DALYS per 100,000 individual. Furthermore, Diagnostic System GmbH introduced a new reagent in the market recently in 2019. It is immunoturbidometric assay that identifies procalcitonin in the serum. Hence, these factors are expected to further boost up the immunoprotein diagnostic testing market.
Key Market Trends

Endocrine Segment is Expected to Hold a Significant Market Share in the Immunoprotein Diagnostic Testing Market

Endocrine segment is expected to exibhit a steady growth in the immuno protein diagnostic testing market. The growing burden of endocrine diseases such as diabetes and the development of products related to immuno diagnostic testing. According to the Centre for Disease Control and Prevention, in 2018, 1.5 million new cases were diagnosed with diabetes in the United States in people aged 18 years and above.

Furthermore, diabetic neuropathy is common consequence of diabetes. According to the study of Journal of Diabetes Research, in 2019, the presence of microalbuminuria is the clinical evidence for diabetic neuropathy. Hence, detection of microablbuminuria is very important in diagnosis of it.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to be a dominant region owing to the rising geriatric population and growing burden of diseases. According to the Institute of Health Metrics and Evaluation, in 2017, the DALYS was found to be around 24,305. According to the U.S. Census Bureau, in the United States around 52 million of population in 2018 were at the age of 65 or above. Older population is at high risk and likely to suffer from chronic diseases due to its weaker metabolic and immune system. Almost a quarter of the older population are diagnosed with diabetes and the number is expected to increase rapidly in the coming decades, according to the study of National Institute of Diabetes and Digestive and Kidney Diseases, 2018. This emerges the need for early detection of the diseases so that a proper treatment can be taken. Thus, it is expected to influence positively on the immunoprotein diagnostic testing market.

Competitive Landscape

Key players that are expected to be dominant in Immunoprotein Diagnostic Testing market are Thermofisher Scientific Inc., Enzo Lifesciences Inc., Randox Laboratories, Abbott, Bio-Rad Laboratories, Inc., Abbott, SERVA Electrophoresis GmbH, F. Hoffmann-La Roche Ltd, Diazyme Laboratories, Inc. and Calbiotech Inc.

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– 3 months of analyst support

レポート目次

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Technological Advancements of Products
4.3 Market Restraints
4.3.1 Expenisive Techniques
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Instruments
5.1.2 Kits & Reagents
5.1.3 Others
5.2 By Technology
5.2.1 Chemiluminescence Assay
5.2.2 Immunofluorescence Assay
5.2.3 Immunoturbidity Assay
5.2.4 Immunoprotein Electrophoresis
5.2.5 Others
5.3 By Application
5.3.1 Infectious Disease
5.3.2 Endocrine
5.3.3 Toxicology
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott
6.1.2 Bio-Rad Laboratories, Inc.
6.1.3 Calbiotech Inc.
6.1.4 Diagnostic System GmbH
6.1.5 Diazyme Laboratories, Inc.
6.1.6 Enzo Lifesciences Inc.
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 Randox Laboratories Ltd.
6.1.9 SERVA Electrophoresis GmbH
6.1.10 Thermofisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS